BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22949152)

  • 1. Double-hit diffuse large B-cell lymphoma.
    Friedberg JW
    J Clin Oncol; 2012 Oct; 30(28):3439-43. PubMed ID: 22949152
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance and application of c-myc in diffuse large B-cell lymphoma].
    Huang WT; Lü N; Guo L
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
    Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A blind skin biopsy diagnosing an intravascular large B-cell lymphoma.
    Deschamps L; Signate A; Delaunay C; Morales I; Warter A; Smadja D; Derancourt C
    Eur J Dermatol; 2011; 21(1):114-5. PubMed ID: 21233067
    [No Abstract]   [Full Text] [Related]  

  • 8. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
    Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
    J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
    Lai S; Venugopal P; Leslie W
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):134-6. PubMed ID: 22402359
    [No Abstract]   [Full Text] [Related]  

  • 11. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Frick M; Dörken B; Lenz G
    Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
    Niino D; Ohsaki K; Arakawa F; Watanabe J; Kimura Y; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Sugita Y; Ohshima K; Okamura T
    Pathol Int; 2011 Jun; 61(6):363-8. PubMed ID: 21615612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.
    Magnoli F; Bernasconi B; Vivian L; Proserpio I; Pinotti G; Campiotti L; Mazzucchelli L; Sessa F; Tibiletti MG; Uccella S
    Cancer Genet; 2018 Dec; 228-229():28-40. PubMed ID: 30553470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F
    Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
    Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E
    Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.
    Rund D
    Leuk Lymphoma; 2014 Sep; 55(9):1966-7. PubMed ID: 24588736
    [No Abstract]   [Full Text] [Related]  

  • 19. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
    Pfreundschuh M
    J Clin Oncol; 2012 Oct; 30(28):3433-5. PubMed ID: 22949148
    [No Abstract]   [Full Text] [Related]  

  • 20. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.